A metabolite of cholesterol promotes breast cancer metastasis through its actions on the endocrine and immune systems

Dr. Erik Nelson, University of Illinois Cancer Center, Department of Molecular & Integrative Physiology
RHPH 164
Date / Time: 
Tuesday, November 21, 2017 - 4:00pm
Dr. Mike Wendt

Obesity and elevated circulating cholesterol are risk factors for breast cancer recurrence, while the use of statins, cholesterol biosynthesis inhibitors widely used for treating hypercholesterolemia, is associated with improved disease-free survival. In this seminar, I will highlight our recent work demonstrating that cholesterol mediates the metastatic effects of a high-fat diet via its oxysterol metabolite, 27-hydroxycholesterol. Intriguingly, the robust effects of 27-hydroxycholesterol on metastasis requires myeloid immune cell function, and we have found that this oxysterol increases the number of polymorphonuclear-neutrophils and γδ-T cells at distal metastatic sites. The pro-metastatic actions of 27-hydroxycholesterol requires both polymorphonuclear-neutrophils and γδ-T cells, and 27-hydroxycholesterol treatment results in a decreased number of cytotoxic CD8+T lymphocytes. Therefore, through its actions on γδ-T cells and polymorphonuclear-neutrophils, 27-hydroxycholesterol functions as a biochemical mediator of the metastatic effects of hypercholesterolemia.

Mega Menu Visual Content